Author

Mustafa Saleh

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

54 Primary Progressive Disease and Outcomes with First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Real-World IMDC Analysis

Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...

É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al. · The Oncologist · 0 citations

Open access Sep 2026

75 Transcriptional Correlates of ARNT Expression and its Impact on Survival Outcomes in Clear-Cell Renal Cell Carcinoma (ccRCC)

Across three cohorts, higher ARNT expression correlated with higher BHS, and a consistent correlation was observed between ARNT and EPAS1 and HIF1A expressions, and a consistent correlation was observed between ARNT and EPAS1 expressions.

Wassim Daoud Khatoun, Ali Hajj Ali, Eddy Saad et al. · The Oncologist · 0 citations

Open access Sep 2026

8 Single Cell Transcriptomic Investigation of Renal Cell Carcinoma (RCC) Reveals Tissue Resident Memory Exhausted CD8+ T Cell Signature Associated with Resistance to Immune Checkpoint Inhibition (ICI)

Abstract Background The current standard of care for advanced RCC is ICI-based combination therapies. However, most patients with advanced RCC develop disease progression despite ICI treatment, suggesting a lack of durable immune response. Although a lack of T cell infiltration or the presence of non-tumor-reactive “by...

Rishabh Rout, S. Kashima, M. Hugaboom et al. · The Oncologist · 0 citations